R&D SpringWorks spins out of Pfizer on rare disease mission A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases.
News Ex-GSK chiefs Witty and Slaoui join biotech investors Former GSK CEO Sir Andrew Witty, and his former drug development chief, Moncef Slaoui have both lined up new jobs as life science investors.
News Janssen axes hep C development with Achillion Johnson & Johnson has ended a collaboration with US biotech Achillion to develop hepatitis C drugs, sending the US biotech firm's shares plummeting.
News Roche hopes blood test will predict immunotherapy efficacy Test could help determine which patients respond to immunotherapies.
News FDA puts hold on AZ and Celgene immunotherapy trials Regulator is exploring safety of immunotherapy combinations in blood cancer
News Boehringer to develop fibrosis treatment with Inventiva Boehringer to progress R&D partnership that began last year
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
